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AbstrAct:
Background: Cerebral venous sinus thrombosis is a rare complication of ulcerative colitis. 
Case presentation: We present a case report of a 19-year-old female patient with ulcerative colitis, 
who developed superior sagittal sinus thrombosis with haemorrhagic transformation. Despite the 
initial treatment with anticoagulant therapy, the patient became comatose, with symptomatic epi-
leptic seizures and compromised cardiorespiratory function. She was transferred to the ICU and put 
on life-support for 3 weeks. She gradually improved and was discharged on low-molecular weight 
heparin and antiepileptic therapy. Oral anticoagulant therapy with warfarin was started 6 months 
later, when the subsequent D-dimers normalized. In the follow-up period, the patient experienced 
another series of symptomatic epileptic seizures and poorly regulated INRs. Therefore, antiepileptic 
and anticoagulation therapies were changed to oxcarbazepine and rivaroxaban. 
Conclusion: Physicians should be aware that treatment of cerebral venous sinus thrombosis with 
haemorrhagic transformation in a patient with ulcerative colitis is very challenging and demanding. 
These patients need to be closely monitored for possible complications that might arise due to the 
concomitant presence of both diseases and possible drug interactions. 
Keywords: cerebral sinus venous thrombosis, ulcerative colitis, “thunderclap” headache, symptom-
atic epilepsy, anticoagulation 
Sažetak:
Uvod: Tromboza vena sinusa mozga je rijetka komplikacija ulceroznog kolitisa.
Prikaz slučaja: Prikazujemo slučaj 19-godišnje bolesnice s ulceroznim kolitisom koja je razvi-
la superiornu trombozu sagitalnog sinusa s hemoragičnom transformacijom. Unatoč početnom 
liječenju antikoagulantnom terapijom, pacijent je postao komatozan, sa simptomatskim epileptičkim 
napadajima i kompromitiranom kardiorespiratornom funkcijom. Pacijentica je prebačena na jedinciu 
intenzivnog liječenja  tijekom naredna 3 tjedna. Postupno se poboljšavala uz terapiju heparina niske 
molekularne mase i antiepileptičku terapiju. Oralna antikoagulantna terapija s varfarinom započela je 
6 mjeseci kasnije, kada su se sljedeći D-dimeri normalizirali. U razdoblju praćenja pacijent je doživio 
niz simptomatskih epileptičkih napadaja i slabo reguliranih INR-ova. Stoga su antiepileptička i an-
tikoagulacijska terapija promijenjene u okskarbazepin i rivaroksaban. 
Zaključak: Liječnici trebaju biti svjesni da je liječenje cerebralne venske sinusne tromboze s hemor-
agičnom transformacijom u bolesnika s ulceroznim kolitisom vrlo izazovno i zahtjevno. Te bolesnike 
treba pomno pratiti zbog mogućih komplikacija koje bi mogle nastati zbog istodobne prisutnosti 
bolesti i mogućih interakcija lijekova.
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introduction
Cerebral venous sinus thrombosis (CVST) is a relatively rare 
condition compared to arterial disease. The estimated incidence 
is 3-4/100.000 in the adult population and up to 7/100.000 in 
children1. It is more common in women than in men, and young 
women (age 20-35 years old) are more frequently affected2.  
CVST can be caused by different conditions, such as colla-
gen-vascular, infectious, structural, hypercoagulable states, hema-
tological, hormonal, medication-related, and others (Table 1).
Inflammatory bowel diseases, such as Crohn disease and 
ulcerative colitis (UC), have also been described as risk factors 
for CVST; it is suspected that hypercoagulable state occurring 
during the disease or the use of corticosteroids in the treatment 
could cause CVST. 
caSe preSentation
We present a case of a 19 year old female patient, who was 
admitted at the University Clinic of Neurology due to strong 
generalized “thunderclap” headache resistant to analgesics that 
was followed by acute onset of right sided hemiparesis and 
hemiparesthesiae 3 days before. On admission the patient was 
conscious, blood pressure was 115/70 mmHg, with right-sided 
hemiplegia and motor dysphasia. Urgent computed tomography 
(CT) of the brain showed a  hypodensity involving the left pa-
rietal cortical and subcortical region with hyperdensities within 
the affected area, suspicious for venous infarction with haemor-
rhagic transformation due to thrombosis of the superior sagittal 
sinus (Figure 1). She had been diagnosed with ulcerative colitis 
one year earlier and was on oral treatment with sulfasalazine 
and azathioprine. Therapy with low-molecular heparin (Clexane 
2x60mg) was initiated.
Blood laboratory analysis showed increased levels of D-dimers 
(12 000 ng/ml), erythrocyte sedimentation rate-ESR (90 mm/h), 
CRP (136 mg/L) and decreased levels of RBC (2,51 10x12/L), 
albumin 27 g/L and Fe 3,7 mmol/l; other values were normal.
Follow up CT of the brain two days after showed worsening of 
Figure 1. CT scan of a venous infarction with hemorrhagic transformation due to 
thrombosis of the superior sagittal sinus
Figure 2. Control CT of the brain that showed massive venous infarction in the left 
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Table 1. Conditions that may cause CVST
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the previous finding, with venous infarction in the left parietal 
cortical and subcortical region, with dimensions 98mmx56mm 
and strong compressive behavior towards cerebral falx and left 
lateral ventricle, with haemorrhagic transformation with dimen-
sions 16mmx9mm and several smaller punctate haemorrhagic 
changes (Figure 2). Antiedematous therapy with mannitol and 
steroids was administered.
During the hospitalization the patient had repeated focal com-
plex motor symptomatic seizures with secondary generalization 
and antiepileptic therapy with carbamazepine was initiated. 
Despite treatment, the patient worsened, she became comatose, 
with right hemiplegia. The fourth day the patient developed ad-
ditional symptomatic focal complex motor seizures with second-
ary generalization and compromised cardiorespiratory function. 
She was transferred to the Intensive Care and Reanimation Unit 
and was intubated and ventilated. The 3 week course was com-
plicated by aspiration pneumonia. Afterwards, she improved and 
was again transferred to the University Clinic of Neurology. 
On admission she was conscious, with bilaterally weakened vesic-
ular breathing in the basal parts on auscultation, with bronchitic 
noises in the middle parts bilaterally. Neurological examination 
showed motor dysphasia and right sided hemiplegia with spastic 
features, hyperreflexia and positive Babinski sign.
Routine laboratory blood analysis showed moderate secondary 
anaemia with decreased levels of RBC, HGB and SeFe, elevated 
WBC and sedimentation, all other values were normal. Coagula-
tion studies showed increased levels of D-dimer and therapy with 
low-molecular heparin (Clexane 2x60mg) was continued.
EEG showed groups of delta waves over the left temporo-occipi-
tal region.
Follow up CT after 10 weeks showed massive hypodense zone in 
the left parietal and left frontal region without compressive be-
havior towards the surrounding structures, i.e. venous infarction 
in the phase of reabsorption (Figure 3, A and B). Through this 
zone smaller hyperdense punctuate zones were seen, that could 
represent smaller haemorrhagic formations.
Genetic mutation investigations for cerebrovascular diseases 
showed heterozygote for A1298C mutation in the gene for 
MTHFR, heterozygote for mutation V34L in the gene for factor 
XIII, homozygote for mutation eNOS-786 T>C, heterozygote 
for mutation 455 G>A in the gene for B-fibrinogen and hetero-
zygote for mutation eNOS G894T and LTA. Other tests (levels 
of antiphospholipid antibodies, protein S and C, antithrombin 
III,  lupus anticoagulant, and the Leiden factor V) were normal. 
The patients still had melena, so after gastroenterohepatologist 
and surgical consultations, proctocolectomy was recommended 
according to the severity of the disease and response to medical 
therapy. The patient was discharged after 2 weeks in a stable 
condition, with mRS score of 4 and treated with anticoagulation, 
gastroprotective, immunomodulatory and physical therapies. 
She came for regular visits every month, and was treated with 
low-molecular heparin (Clexane) for a period of 6 months (with 
gradually decreasing of the dose), due to melena. After 6 months 
the level of the D-dimer normalized. Melena resolved and she 
was switched to oral anticoagulant therapy with warfarin. Her 
neurological status slightly improved as well, she was able to 
walk with a stick on her own, and her speech also improved, 
with mRS of 3. Subsequent CT scan showed large postapoplec-
tic sequela (Figure 3, C and D). However, 14 months after the 
initial event of CVST, the patient experienced another series 
of focal complex motor seizures with secondary generalization. 
The dosage of carbamazepine was initially increased, but later 
switched to oxcarbazepine. Although the patient did not have 
any epileptic seizures in the following 6 months, she complained 
of transient side effects from oxcarbazepine (alopecia and skin 
rash on her back). Gradually, the side effects withdrew, and the 
patient did not experience them anymore. Nineteen months after 
the initial event, control INR showed poor regulation1,3, mostly 
due to green salad intake and its interaction with warfarin. 
Therefore, rivaroxaban of 15mg daily was recommended and 
warfarin was stopped.
diScuSSion
UC is a type of chronic inflammatory bowel disease (IBD) of 
unknown etiology that causes inflammation and ulcers in the the 
colon and rectum.  It is a consequence of complex interaction 
of environmental factors and genetic susceptibility. UC may 
affect any age group, but most commonly appears in age groups 
between 15-30 and 50-70 years. Approximately 40% of the pa-
tients have extra-intestinal manifestations in skin, joints, bones, 
lungs, blood, eyes, kidneys, liver, peripheral and central nervous 
system3. Patients with IBD have high thromboembolic risk, with 
an annual incidence varying between 0,5 to 6,7%4,5. Their risk 
for a thromboembolic event is increased 3-4 fold, compared to 
healthy controls4,6. 
CVST has been reported as rare, but severe complication of UC, 
with the annual incidence ranging from 1.3% - 7.5% 7, 8. The 
clinical presentation of CVST, consisting of headaches, focal 
signs, seizures, or encephalopathy, and the sites of the venous 
occlusions are similar to the usual cerebral venous thrombosis. 
Figure 3. Control CT scan X weeks (A and B) and one year (C and D) after the 
initial event of CVST, showing large postapoplectic sequela
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It can appear from 2 months to 17 years after the first attack of 
IBD. Sometimes, the diagnosis of IBD is established only when 
CVST occurs9. 
Katsanos et al. have retrospectively reviewed 65 case reports from 
IBD patients complicated with CVST, published in the period 
from 1967-201210. Sources included MEDLINE and EMBASE 
and they included only papers written in English. We searched 
MEDLINE for case reports published in the period 2012-2019 
and found 13 papers describing total of 17 cases with UC and 
CVST (Table 2).
Mahmoud et al. (2013) have described an 11 year old male patient 
with 3 months history of UC who presented as pseudotumor 
cerebri due to superior sagittal sinus thrombosis during an acute 
exacerbation of his colitis, that was successfully treated with hepa-
rin and then warfarin11.
Cojocary et al. (2014) published cerebrovascular complications in 
9 patients with IBD (6 with Crohn’s disease (CD) and 3 with UC, 
4 of them during acute disease at admission12. Cerebrovascular 
complications were: CVT-7 cases (5 CD and 2 UC) and ischemic 
stroke-2 cases (1 CD and 1 UCC). Out of 7 cases with CVT 5 
were superior sagittal sinus thrombosis (SSS), 2 SSS and transverse 
and sigmoid sinus thrombosis. Significantly high serum levels of 
homocysteine were observed in all patients. No correlation be-
tween high dose corticosteriods and its decrease, the activity of the 
IBD, the duration of the disease, and the onset of cerebrovascular 
complications was found. Tendency to hypercoagulability, even in 
the inactive state of the IBD was observed. The outcome of cases 
was favorable, with the remission of symptoms in CVT cases and 
with residual motor deficits in ischemic stroke patients.
Shaik et al (2014) presented a pre-teenager with newly diagnosed 
UC and acute headache, altered mental status and bilateral lower 
extremity weakness, with thombosis in the vein of Galen and 
straight sinus, demonstrated on CT. Despite therapy with hepa-
rin, the patient clinically deteriorated and became unresponsive, 
and was therefore taken for endovascular
treatment. A novel endovascular approach had been performed 
with combined use of Solitaire FR and Penumbra devices to 
enhance access to the straight sinus and to limit intraprocedural 
blood loss. The posttreatment CT demonstrated a decrease in 
hyperattenuation within the vein of Galen and straight sinus. 
The neurologic status improved within 24 h. The patient was 
discharged home with a normal neurologic
examination13.
Defillipis et al, 2015 reported 6 IBD patients with cerebral 
venous thrombosis, of which 4 had active UC14. The patients 
presented with hours to days of headache and were found to have 
venous thrombosis on imaging. All patients were treated with 
therapeutic anticoagulation. There were two deaths; one patient 
Author/year Age Gender Active UC UC treatment Neurological symptoms CVST location Risk factors CVST treatment Outcome
Mahmoud et al. 2013 11 M Yes Prednizolon Headache, orbital pain, 
photophobia, transient 
blurred vision, vomiting
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DeFillipis et al, 2015 30 M Yes Corticosterioids / / / LMWH Partially 
recovered
DeFillipis et al, 2015 12 M Yes Corticosterioids / / / LMWH Completely 
recovered
DeFillipis et al, 2015 10 M Yes Corticosteroids / / / Heparin drip Lethal 
outcome
DeFillipis et al, 2015 11 F Yes Corticosteroids / / / Heparin Lethal 
outcome










Meher et al, 2016 38 F No Oral steroids, 5-
ASA, 
Sulfasalazine











Table 2. Case reports from patients with UC and CVST published in the period 2012-2019
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became comatose and died despite anticoagulation while the 
other recovered well from the sinus thrombosis but died after a 
bowel perforation 3 weeks later. Five patients were being treated 
with corticosteroids at the time of the occurrence of CVT. Three 
patients were on anti-tumor necrosis factor inhibitors, including 
two on infliximab and one on certolizumab. The most common 
locations for CVT were sagittal sinus and transverse sinus, both 
occurring in three patients. However, four patients had multiple 
cerebral thrombi involving both deep cerebral and superficial 
cortical veins. One patient had the heterozygous C677T mu-
tation in the MTHFR gene. Three patients had elevated factor 
VIII activity attributed to ongoing inflammation. All patients 
were treated with therapeutic anticoagulation and subsequently 
maintained on low molecular weight heparin or warfarin for 
6 months or longer. Altogether two patients died, in which 
one became comatose and died despite anticoagulation. The 
patient had a progression of infarcts in the left hippocampus, 
right internal capsule, right thalamus and right medial temporal 
lobe, with increasing edema, mass effect and midline shift. The 
other patient recovered well following the sinus thrombosis with 
only mild residual right-sided weakness and was discharged on 
low molecular weight heparin. She was readmitted to another 
hospital 3 weeks later after experiencing a few days of abdom-
inal pain, rectal bleeding and respiratory distress. The patient 
was found unresponsive by the emergency medical services. A 
head computed tomography (CT) revealed no hemorrhage or 
evidence of ischemic stroke. The patient was found to have bowel 
perforation and underwent surgical intervention twice. She died 
from post-operative complications. Of the four patients who 
recovered, only one patient had any residual neurological deficits 
that were limited to trace right facial weakness, right-sided ataxia 
and mild sensory loss on the right hand and foot.
Calcagno et al, 2015 have described a case of a 22 year old male 
with UC in treatment with mesalazine and prednisone present-
ing with headache and speech disturbances 15. A magnetic reso-
nance imaging of the brain showed a left temporal hemorrhagic 
infarct with thrombosis of the ispilateral superficial vein and 
sigmoid venous sinus. No cause of thrombophilia was detected. 
Anticoagulation with heparin was started which was changed to 
oral anticoagulation with warfarin. The patient was discharged 
ten days after admission.
Meher at al, 2016 have reported a case of a 38-year-old female 
with a history of UC in remission who developed sudden onset 
headache, blurring of vision and seizures16. Subsequent diagno-
sis of cerebral venous sinus thrombosis (transverse and sigmoid 
sinus) was made with MRI venography and treated with low 
molecular weight heparin with complete resolution of symptoms. 
Various mechanisms have been proposed as possible explanations 
for thrombosis in UC, such as hypercoagulation (elevated FVIII, 
fibrinogen, decrease in antithrombin, protein S and protein C), 
hypofibrinolysis [elevated PAI-1 and lipoprotein (a)], platelet ab-
normalities, endothelial dysfunction (increased von Willebrand 
factor) and immunological abnormalities (antiphosphlipid an-
tibodies)17, 18. It has been suggested that the interaction between 
the coagulation cascade in the body and cytokine mediators of 
chronic inflammation and also the inflammatory process can 
itself activate the coagulation cascade18. Beside inflammation, the 
drugs used in the treatment (corticosteroids and sulfonamides) 
contribute to the thrombophilic tendency17,19. Some authors 
suggest that the majority of thrombotic events occur during the 
active phase of disease, however, others disagree. For example, 
Kristensen et al., reported a significant direct association of 
disease activity of IBD with increased risk of morbidity and mor-
tality20, while Katsanos et al., reported the presence of CVST in 
the active phase in 78.4% and in the inactive phase of the disease 
in 21.6%21.
Risk factors and concomitant causes of CVST were systemat-
ically searched for in our patient. We found hypercoagulable 
state in our patient, with increased D-dimer levels. Also, biologic 
markers of inflammation such as elevated leukocyte count and 
CRP were registered and the patient was in an active phase of her 
UC (with continuous bleeding). 
Genetic mutation investigations for cerebrovascular diseases 
showed (among other mutations), a heterozygote for A1298C 
mutation in the gene for methylenetetrahydrofolate reductase 
(MTHFR). Reports from the literature have also shown defective 
activity of MTHFR among patients with UC, which is linked to 
folate and vitamin B12 deficiency and causes hyperhomocystein-
emia-related thrombosis22. Data from the literature have shown 
that patients with UC have more frequently lower circulating 
protein S levels than normal controls 23, 24 and reduced levels of 
antithrombin III. But, in more than 50% of the patients with 
UC, no predisposing factor can be found25. The values of protein 
C, S and antithrombin III in our patient were in normal range.
The first-line treatment for CVST is adjusted-dose unfraction-
ated heparin or low-molecular-weight heparin (LMWH), but 
its risks should be carefully weighed in light of possible hem-
orrhagic complications 26. When the patient is relatively stable, 
oral anticoagulant therapy with warfarin is continued with an 
INR target 2-3 27. Steroids reduce the intracerebral edema and 
are also indicated in the active cases of ulcerative colitis28. Our 
patient had an active form of UC with constant bleeding from 
the gastrointestinal tract. Despite this fact, therapy with LMWH 
was initiated, as well as antiedematous therapy with mannitol 
and steroids. But, the patient’s neurologic and physical condition 
gradually worsened and she had to be put on life-support for a 
period of 3 weeks. Her condition stabilized after this period and 
she became conscious, able to breathe on her own. Therapy with 
LMWH continued for a period of 6 months because she has had 
a hypercoagulable state. After the UC went into remission and 
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bleeding had stopped, we were able to switch her on oral antico-
agulant therapy with warfarin with satisfactory level of INR. She 
has continued with oral anticoagulant therapy in the following 
period, without any side effects. However, when we encountered 
difficulty regulating the INR, with a possible risk for recurrent 
thrombosis, we made a choice to stop warfarin and introduce 
rivaroxaban. We searched MEDLINE for similar cases, and only 
found one case report, where rivaroxaban was prescribed to a 17 
years old female with a CVST and Crohn’s disease29. There were 
also other case reports regarding administration of rivaroxaban in 
patients with CVST, but without known UC30, 31, 32. 
Another problem that we have encountered was the recurrence of 
late onset epileptic seizures.  The study of Kalita et al. 33 showed 
that up to 5,6% of their patients with CVST had late recur-
rence of seizures. Recent study by the VENOST Study Group34 
showed that epileptic seizures had no effect on prognosis of 
CVST. 
Overall, the prognosis is usually good, but a few cases were fatal 
9, 21. There are recommendations for prophylaxis of thromboem-
bolic phenomena (including CVST) in patients with IBD. The 
Canadian Gastroenterology Association35 and the British Society 
of Gastroenterology36 recommend pharmacological thrombopro-
phylaxis in patients requiring hospitalization for moderate-severe 
IBD and without severe bleeding.    
concluSion
CVST is a devastating complication of IBD, especially, UC. This 
case report signifies the importance of considering the diagnosis 
of CVST in a case of IBD. Any sudden neurological symptoms 
such as headache, hemiparesis and seizures in a patient with UC 
should initiate urgent diagnostics in order to prevent the compli-
cations of the disease. Physicians should be aware that treatment 
of cerebral venous sinus thrombosis with haemorrhagic trans-
formation in a patient with ulcerative colitis is very challenging 
and demanding. These patients need to be closely monitored for 
eventual complications that might arise due to the concomitant 
presence of both diseases and possible drug interactions. Our 
patient with CVST associated to UC is the first case reported in 
literature treated with rivaroxaban because of INR poor regula-
tion.
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